RT Journal Article SR Electronic T1 Does in utero HIV-exposure influence infant development and immune outcomes? Findings from a pilot study in Pretoria, South Africa JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19003889 DO 10.1101/19003889 A1 Marina White A1 Ute D Feucht A1 Eleanor Duffley A1 Felicia Molokoane A1 Chrisna Durandt A1 Edana Cassol A1 Theresa Rossouw A1 Kristin L Connor YR 2019 UL http://medrxiv.org/content/early/2019/09/20/19003889.abstract AB HIV-infected infants show altered growth, brain development, and immune function. Yet, it remains unclear how detrimental fetal exposure to maternal HIV infection is to the development of the uninfected infant. A pilot study was conducted at Kalafong Hospital in Pretoria, South Africa, to better understand how maternal HIV infection influences infant outcomes. We hypothesised that in utero HIV-exposed, uninfected (HEU) infants would have poorer postnatal development and altered innate immune composition compared to HIV-unexposed, uninfected infants (HUU). Infant growth, neurodevelopment (Guide for Monitoring Child Development [GMCD]) and levels of monocyte subsets (CD14, CD16, and CCR2 expression [flow cytometry]) were measured in infants at birth and 12-weeks. HEU infants had lower head circumference and elevated CCR2+ (% and median fluorescence intensity) on monocytes at birth compared to HUU. Most infants met GMCD milestones at 1-3 and 3-5 months. Our findings that HEU infants had reduced head circumference and increased levels of migratory monocytes at birth, which has been associated with poor motor and cognitive outcomes, is consistent with our motor results within 5 months of age. Elevated levels of migratory monocytes may initiate pro-inflammatory pathways that target the brain, impacting neurodevelopment and lifelong health.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research is funded by the Collaborative Initiative for Paediatric HIV Education and Research (CIPHER), the Faculty of Science, Carleton University, and the Canadian Institutes of Health Research (CIHR). MW is supported by a Canadian Graduate Scholarship-Master’s from CIHR.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.